Roche invests $142m in Shanghai for infectious disease research
This article was originally published in Scrip
Roche is showing its confidence in treatments for infectious diseases in China through a substantial new investment - as much as CHF136 million ($142 million) – to build a new laboratory facility for its R&D Innovation Center in Shanghai.
You may also be interested in...
German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.